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Meta-analysis identiﬁes seven susceptibility loci
involved in the atopic march
Ingo Marenholz et al.#
Eczema often precedes the development of asthma in a disease course called the ‘atopic
march’. To unravel the genes underlying this characteristic pattern of allergic disease, we
conduct a multi-stage genome-wide association study on infantile eczema followed by
childhood asthma in 12 populations including 2,428 cases and 17,034 controls. Here we
report two novel loci speciﬁc for the combined eczema plus asthma phenotype, which are
associated with allergic disease for the ﬁrst time; rs9357733 located in EFHC1 on chromo-
some 6p12.3 (OR 1.27; P¼ 2.1 10 8) and rs993226 between TMTC2 and SLC6A15 on
chromosome 12q21.3 (OR 1.58; P¼ 5.3 10 9). Additional susceptibility loci identiﬁed at
genome-wide signiﬁcance are FLG (1q21.3), IL4/KIF3A (5q31.1), AP5B1/OVOL1 (11q13.1),
C11orf30/LRRC32 (11q13.5) and IKZF3 (17q21). We show that predominantly eczema loci
increase the risk for the atopic march. Our ﬁndings suggest that eczema may play an
important role in the development of asthma after eczema.
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T
he atopic or allergic march describes the sequential
progression of different allergic conditions frequently
observed in children with IgE-antibody responses against
common environmental allergens (atopy)1,2. Generally, eczema
(atopic dermatitis) is the ﬁrst clinical manifestation of the atopic
march followed by asthma and/or allergic rhinitis. About 20–30%
of infants with eczema undergo this unfavourable disease course,
which is associated with severe and persistent allergic disease
manifestations3,4.
In recent years, the concept of the atopic march has received
increasing attention5–7. Multiple progression patterns have been
discussed as allergic conditions may manifest in different orders1.
A breakthrough in the understanding of the atopic march was
the discovery of the ﬁlaggrin loss-of-function mutations that
provided genetic evidence linking skin barrier deﬁciency to
eczema and subsequent asthma development8,9.
We aimed to identify the genetic factors underlying the atopic
march in a genome-wide association study (GWAS). We used the
most common phenotype representing the atopic march, which is
eczema followed by asthma10. In the discovery phase, six GWASs
were included and another six populations were used for
replication. Our meta-analysis identiﬁes seven susceptibility loci
at genome-wide signiﬁcance of which two are associated with
allergic disease for the ﬁrst time. In addition, we ﬁnd an
overrepresentation of eczema loci among the atopic march loci.
Deciphering the molecular determinants of the atopic march may
point to novel therapeutic approaches to prevent or at least arrest
the atopic march.
Results
Meta-GWAS of the discovery populations. To identify genes
involved in the atopic march, we performed GWASs in six
populations including 1,151 cases and 10,030 controls of
European descent, and meta-analysed the results (Supplementary
Fig. 1; Supplementary Table 1). We used a strict phenotype
deﬁnition focusing on individuals with early-onset eczema (up to
3 years of age) and childhood asthma (up to 16 years of age;
Supplementary Table 2). Association with disease was calculated
by logistic regression using an additive allele-dosage model. For
each population of the discovery set, more than two million single
nucleotide polymorphisms (SNPs) imputed from the HapMap 2
Utah Residents with Northern and Western European Ancestry
(CEU) reference panel were available.
More than 1.6 million SNPs passed the quality control criteria
in all study populations and remained in the meta-analysis (see
Methods section). There was little evidence for inﬂation of test
statistics (lGC(meta)¼ 1.07, l1,000¼ 1.03 (ref. 11); Supplementary
Fig. 2). Several SNPs within the epidermal differentiation
complex (EDC) on chromosome 1q21.3 reached genome-wide
signiﬁcance (Fig. 1). We found strong correlation between the
lead SNP rs12081541 (odds ratio (OR) 1.61; P¼ 8.5 10 11),
and a nearby loss-of-function mutation in the ﬁlaggrin gene (FLG
R501X, D0 ¼ 0.86, r2¼ 0.18), a well-known risk factor for eczema
and eczema-associated asthma8,9. After adjusting for FLG-null
mutations in the study populations with available genotypes, the
association signal in the EDC disappeared (Supplementary Fig. 3),
indicating that there is no additional susceptibility locus within
this region.
Replication and combined meta-analysis. In total, 54 SNPs
from regions with moderate association in the discovery set
(1 10 44P45 10 8; Fig. 1) were subjected to replication in
ﬁve independent study populations including 864 atopic march
cases and 5,346 controls of European descent (replication set 1;
Supplementary Table 1). When multiple associated SNPs were
located in the same region, we selected the best SNP per 1-Mb
window. We meta-analysed the results of the study populations
in replication set 1 (Supplementary Table 3) and, in addition,
performed a combined meta-analysis including the discovery set.
In the combined meta-analysis, four additional susceptibility
loci were associated with the atopic march at genome-wide
signiﬁcance (Po5 10 8; Table 1).
The susceptibility loci IL4/KIF3A on chromosome 5
(rs17690965; OR 1.24; P¼ 4.5 10 8) and OVOL1 on chromo-
some 11 (rs479844; OR 1.25; P¼ 3.6 10 10) were previously
identiﬁed in a GWAS on eczema (Supplementary Table 4)12.
In addition, the association signal near C11orf30/LRRC32
on chromosome 11 (rs2155219; OR 1.33; P¼ 1.8 10 15)
conﬁrmed a susceptibility locus for eczema and eczema-
associated asthma13,14. Finally, the chromosomal region around
rs10445308 (OR 1.22; P¼ 4.7 10 8), which is located in an
intron of IKZF3 on chromosome 17 was found previously in
studies on childhood asthma15–17, self-reported allergy18 and
asthma plus hay fever (Supplementary Table 5)19. Regional
association plots of the atopic march susceptibility regions in the
populations of the discovery set are depicted in Supplementary
Fig. 4.
Importantly, two novel susceptibility loci for the atopic march
were identiﬁed: both variants (rs9357733 and rs993226) were
signiﬁcantly associated in replication set 1 after correction for
multiple testing (Po0.05/54 (9.3 10 4); Supplementary
Table 3) but did not reach genome-wide signiﬁcance in the
combined analysis. Both SNPs were therefore genotyped in a
second independent replication set of 413 cases and 1,658
controls from Europe (replication set 2), and reached genome-
wide signiﬁcance in the combined meta-analysis including all
data sets (Table 1).
Characterization of the two novel atopic march loci. As a
preliminary step towards understanding the functional basis of
the novel atopic march loci, we evaluated their association with
gene expression in lymphoblastoid cell lines of 373 European
individuals from the 1000 Genomes Project20, reviewed
their functional annotations in ENCODE Consortium (http://
genome.ucsc.edu/ENCODE/)21 and Roadmap Epigenomics
Consortium data (http://www.roadmapepigenomics.org/)22, and
surveyed relevant mouse models (http://www.informatics.jax.org/
phenotypes.shtml)23.
On chromosome 6p12.3, rs9357733 was associated with the
atopic march (OR 1.27; P¼ 2.1 10 8; Table 1) with consistent
risk allele and effect size across all study populations
(Supplementary Fig. 5). It is located 20Mb away from the
established risk variants for eczema and for asthma on 6p21.3
and not in linkage disequilibrium with them. The linkage
disequilibrium block around rs9357733 contains the genes encoding
the progestin and adipoQ receptor family member VIII (PAQR8),
the EF-hand domain (C-terminal)-containing protein 1 (EFHC1)
and the translocation associated membrane protein 2 (TRAM2;
Supplementary Fig. 4). Strongest association was observed in intron
2 of EFHC1, which is ubiquitously expressed (http://fantom.gsc.ri-
ken.jp/zenbu/)24. We used SNAP (SNP Annotation and Proxy
Search; http://www.broadinstitute.org/mpg/snap/ldsearch.php)25 to
screen for functional SNPs in linkage disequilibrium with rs9357733
and identiﬁed rs3804508 (r2¼ 1) located in a predicted enhancer
(Supplementary Fig. 6). The corresponding enhancer marks were
predominantly found in cells derived from target organs of allergic
disease such as skin keratinocytes, skin ﬁbroblasts and lung
ﬁbroblasts, and were absent in immune cells.
A second novel variant associated with the atopic march,
rs993226 (OR 1.58; P¼ 5.3 10 9; Table 1), is located on
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chromosome 12q21.3, 1.36Mb distal of transmembrane and
tetratricopeptide repeat containing 2 (TMTC2) and 370 kb
proximal of solute carrier family 6 (neurotransmitter transporter),
member 15 (SLC6A15; Supplementary Fig. 4). Little is known
about the more distant gene TMT2, which encodes a membrane
protein of the endoplasmatic reticulum involved in calcium
homeostasis26. SLC6A15 encodes a Naþ /Cl -dependent
membrane transporter for neutral amino acids, B(0)AT2, which
exhibits a speciﬁc gene expression pattern predominantly in cells
derived from skin, respiratory tract and brain (http://
fantom.gsc.riken.jp/zenbu/)24. However, there was no evidence
from expression quantitative trait locus (eQTL) or epigenetic data
for an involvement of rs993226 in the regulation of these genes
(Supplementary Table 6).
The role of eczema loci and asthma loci in the atopic march.
Next, we evaluated whether previously reported susceptibility loci
for eczema or asthma were associated with the atopic march in our
discovery meta-analysis. From the catalog of published GWASs27,
we selected all SNPs which were associated with asthma or eczema
at genome-wide signiﬁcance level (Supplementary Tables 4 and 5),
and examined association in our discovery set. All ﬁve GWAS loci
previously associated with both traits (IL6R, IL1RL1/IL18R1,
RAD50, human leukocyte antigen (HLA) region and C11orf30)
replicated at Po0.001 in our data set. For the European
susceptibility loci that were previously identiﬁed only in studies
on eczema, we found the same risk alleles in our study; seven out
of eight were associated with the atopic march (Po0.05;
Supplementary Table 4). In contrast, only 3 out of 12 European
loci identiﬁed only in GWAS on asthma were associated at Po0.05
(Supplementary Table 5). Moreover, ranking the known risk
variants, which were speciﬁc for asthma or eczema according to
their statistical signiﬁcance in the discovery meta-analysis yielded a
signiﬁcant enrichment of eczema loci among the SNPs associated
with the atopic march (P¼ 0.0078; Fig. 2).
Subphenotype analysis for the atopic march loci. Since we
studied the combined phenotype of eczema plus asthma, we
investigated whether the identiﬁed associations were driven by
either eczema or asthma. We performed this analysis in the
large population-based Avon Longitudinal Study of Parents
and Children (ALSPAC) birth cohort (n¼ 7,829 genotyped
individuals). The strengths of ALSPAC are longitudinal data on
eczema and on asthma throughout childhood. This allowed us to
deﬁne all three phenotypes (atopic march, eczema alone and
asthma alone) in a single, unselected cohort and to use identical
controls for all three comparisons. In line with the meta-analysis,
six of seven loci were signiﬁcantly associated with the atopic
march (Po0.05) and only one locus just failed signiﬁcance
(Table 2). The four loci originally discovered through GWAS on
eczema (FLG, IL4/KIF3A, OVOL1 and C11orf30/LRRC32) did not
reveal an effect on asthma alone. Compared with eczema alone,
the excess risk of these loci on the atopic march was not
signiﬁcant (Supplementary Tables 7 and 8) although a trend for
FLG-null mutations and the C11orf30/LRRC32 locus was
observed. For both of these loci, an effect on disease progression
from eczema to asthma has previously been demonstrated9,13,
suggesting that our current analysis may have lacked power to
detect such an effect. The previously identiﬁed asthma locus
IKZF3 revealed a different association pattern with a stronger
effect on asthma than on the atopic march. Interestingly, the two
new loci conferred risk for the atopic march but not for eczema
alone or asthma alone (Table 2).
Assessment of a potential selection bias. All cases included in
this meta-analysis of the atopic march had participated in pre-
vious GWAS on eczema or asthma. Therefore, we had to rule out
that the observed excess of eczema susceptibility loci was due to
an overrepresentation of eczema studies. The inclusion of study
populations that were originally recruited through eczema, for
example, may favour the discovery of eczema loci. However, only
two study populations were recruited through eczema (n¼ 402
atopic march cases), while six were unselected (n¼ 1,137 atopic
march cases) and three were recruited through asthma (n¼ 476
atopic march cases; Supplementary Table 9). In addition, we
determined to what extent our samples contributed to the
discovery of eczema loci and asthma loci in previous GWAS.
Considering the cases in previous eczema and asthma GWAS, on
an average only 10.8 and 11.0%, respectively, were included in the
current atopic march study (Supplementary Table 10). It is
therefore unlikely that the prominent role of eczema loci in our
study was due to a selection bias.
Discussion
The atopic march describes disease progression from infantile
eczema to allergic airway disease in childhood and is associated
with severe and persistent allergic disease manifestations. Here,
we report the ﬁrst GWAS on the atopic march. We identiﬁed
seven genome-wide signiﬁcant loci, of which two susceptibility
loci, in EFHC1 on chromosome 6p12.3 and between TMTC2 and
SLC6A15 on chromosome 12q21.3 were associated with allergic
disease for the ﬁrst time.
Coding variants in EFHC1 have been implicated in juvenile
forms of epilepsy28–32. In a knockout-mouse model, reduced
beating frequency of the cilia of ependymal cells in the brain due
to lack of Efhc1/myoclonin1 was identiﬁed as potential disease
mechanism33. Interestingly, Efhc1 was also detected in motile cilia
of tracheal epithelium in mice34. The mucociliary epithelium is
important for the defence against inhaled pathogens and allergens
and ciliary dysfunction is a feature of severe asthma35.
Association between epilepsies and allergic diseases in
childhood has recently been demonstrated36, which may point
to a common molecular mechanism or to pleiotropic effects.
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Figure 1 | Association results of the meta-GWAS on the atopic march.
Manhattan plot shows the P values over the chromosomal positions of all
SNPs of the discovery set (1,151 cases versus 10,030 controls). Red and
black lines indicate the thresholds for genome-wide signiﬁcance
(Po5 108) and for entering the replication phase (Po1 104),
respectively.
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SNPs in SLC6A15 were previously associated with depression,
stress-induced cortisol secretion and obesity-related pheno-
types37–39. A potential functional role of SLC6A15 in the atopic
march is suggested by a recent study demonstrating selective
inhibition of B(0)AT2 by the histamine H1 receptor antagonist
loratadine40, which is clinically used for the treatment of allergic
disease. Further studies will be necessary to elucidate a potential
functional role of this genomic region. Interestingly, both novel
loci revealed no effect on eczema alone or asthma alone. In
agreement with these results, they were not found in previous
GWAS on either trait and may represent novel disease
mechanisms reinforcing the existence of a speciﬁc atopic march
phenotype.
In our study, GWAS loci for eczema ranked signiﬁcantly
higher than asthma loci. In addition, we observed a stronger effect
of the atopic march loci on eczema alone than on asthma alone
for four of the ﬁve established allergic disease loci. These results
suggest that genes triggering eczema are the predominant driver
of the atopic march. In contrast, the majority of the GWAS loci
for asthma seem to be more involved in an eczema-independent
phenotype, supporting genetic heterogeneity in asthma
susceptibility. This ﬁnding highlights the role of the skin as the
interface between host and environment in shaping local and
systemic immune responses that induce chronic inﬂammation
and may affect distant organs in the host41. In mice, it has
been demonstrated that enhanced transcutaneous penetration
of allergens promotes the formation of allergen-speciﬁc IgE
antibodies42,43 and bronchial hyperresponsiveness43. In humans,
a strong association of FLG-null mutations with eczema, with
disease progression to asthma, but not with asthma alone is well
documented8,9. This ﬁnding provided the ﬁrst genetic link
between the loss of a skin-speciﬁc-protein, cutaneous barrier
deﬁciency, eczema and subsequent asthma development.
Furthermore, the importance of infantile eczema in subsequent
asthma susceptibility is underlined by epidemiological data in the
ALSPAC cohort indicating that early eczema confers a 4.3-fold
increase in asthma risk (OR 4.33; 95% conﬁdence interval (CI)
3.72–5.01, Po0.0001). A causal relationship between eczema and
this asthma subtype would have important implications for
interventional strategies. Since no cure for asthma exists, one
might speculate that modulation of skin integrity early in infancy
could be an effective strategy to prevent not only eczema but also
the atopic march in a subset of patients. Recently, skin emollient
therapy in neonates yielded promising results regarding eczema
prevention5,44,45. However, a long-term effect on asthma in these
children still remains to be demonstrated. Epidemiological studies
demonstrating an increased asthma risk in children with early
eczema, clearly support the concept of the atopic march and
the phenotype under study46–49. In the largest study on the
progression of multiple allergic diseases, 60.7% of allergic children
developed eczema ﬁrst10. Of all children with eczema, 86% had it
as their ﬁrst allergic condition, indicating that it is uncommon to
develop eczema after asthma or allergic rhinitis. The development
of all three conditions, eczema, asthma and allergic rhinitis was
unusual occurring in only 2.3% of all children. Therefore,
deﬁning the atopic march based on all three allergic diseases
may underestimate its prevalence50. Among all children with
multiple allergic diseases, the single largest group were those with
eczema followed by asthma (38.3%), the phenotype used in our
current study.
Other atopic march patterns exist as allergic conditions may
occur in different orders. In addition, since eczema and asthma
are common diseases, they may also co-manifest coincidentally.
Thus, the identiﬁcation of known eczema and asthma loci in this
study may reﬂect the underlying association with each disease
independently. In addition, the role of less prevalent allergic
manifestations in the atopic march still needs to be resolved. For
food allergy, mouse models point to a potential involvement in
the atopic march51,52, but robust data from longitudinal cohorts
are sparse53–56.
Some limitations of our study need to be discussed. Although
most of our study populations selected strict controls by the
Table 1 | Association results of susceptibility loci associated with the atopic march.
SNP ID* Chr Positionw EA AA Setz AF OR 95% CI P value Genes
rs12081541y (i) 1 150707990 c t D 0.091 1.61 1.41–1.89 8.5 10 11 CRNN/LCE5A (FLG)
rs17690965 (i) 5 132058566 c g D 0.259 1.28 1.16–1.42 1.5 106 IL4/KIF3A
R1 0.271 1.18 1.05–1.32 4.8 10 3
Combined 0.264 1.24 1.15–1.33 4.5 108
rs9357733 (i) 6 52400095 a g D 0.815 1.29 1.13–1.46 9.5 10 5 EFHC1
R1 0.807 1.27 1.11–1.45 5.1 104
R2 0.792 1.22 1.01–1.47 0.038
Combined 0.808 1.27 1.17–1.38 2.1 108
rs479844 (g) 11 65308533 g a D 0.558 1.28 1.16–1.41 3.6 10 7 AP5B1/OVOL1
R1 0.563 1.22 1.25–1.54 2.0 104
Combined 0.560 1.25 1.24–1.43 3.6 10 10
rs2155219 (i) 11 75976842 t g D 0.481 1.28 1.17–1.41 1.5 10 7 C11orf30/LRRC32
R1 0.494 1.39 1.25–1.54 1.2 109
Combined 0.487 1.33 1.24–1.43 1.8 10 15
rs993226 (g) 12 83410704 g t D 0.037 1.58 1.27–1.96 4.2 10 5 SLC6A15/TMTC2
R1 0.033 1.59 1.23–2.04 4.0 104
R2 0.027 1.57 1.05–2.35 0.028
Combined 0.034 1.58 1.35–1.84 5.3 109
rs10445308 (i) 17 35191573 c t D 0.530 1.25 1.14–1.37 2.9 106 IKZF3
R1 0.528 1.18 1.05–1.30 2.9 10 3
Combined 0.529 1.22 1.14–1.30 4.7 108
AA, alternative allele; AF, effect allele frequency; EA, effect allele; CI, conﬁdence interval; OR, odds ratio.
*(i), imputed SNP; (g), genotyped SNP.
wGenomic positions were based on human genome reference NCBI Build 36.3.
zD, discovery set; R1, replication set 1; R2, replication set 2; combined, combined analysis of D and R1 and of D, R1 and R2 (rs9357733 and rs993226 only), respectively.
yrs12081541 represents the known FLG risk locus and was not subjected to replication.
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absence of eczema and asthma, others used population-based
controls with unknown disease status. Accordingly, the presence
of affected individuals among controls may have decreased the
power of these studies. In addition, we did not use atopy status in
our meta-analysis due to missing data in some populations.
Where available, atopy data were very heterogeneous between
studies regarding age at testing, assay used, number of data points
and allergens tested. The inclusion of atopic controls may have
reduced the power to detect atopy-related genes involved in the
atopic march. However, homogeneous effects of the atopic march
loci across our study populations (Supplementary Fig. 5) using
selected and unselected (population-based) controls pointed to a
minor effect of the selection process.
We did not investigate allergic rhinitis in our study because
reliable phenotype data were not available for all study
populations. As a consequence, our results could be biased
towards genes involved in eczema or asthma rather than allergic
rhinitis. However, the only signiﬁcant locus identiﬁed in GWAS
on allergic rhinitis, C11orf30/LRRC32 (ref. 57), is a known risk
factor for eczema-associated asthma and hay fever13, suggesting
that similar mechanisms may be involved in the atopic march
from eczema to asthma and from eczema to allergic rhinitis.
For the phenotype deﬁnition, we required early eczema to have
manifested by 3 years of age and childhood asthma by 16 years.
However, in several populations phenotype data were not
available for the complete time periods (Supplementary
Table 2). Thus, those individuals who developed eczema and
asthma within the missing time window may have been lost as
cases. Their misclassiﬁcation as controls is unlikely because this
would require that both conditions, eczema and asthma,
manifested within the respective missing period. In addition, a
recall bias in retrospectively collected data can give rise to a loss of
cases. Although most studies relied on actual or reported doctor’s
diagnoses, a few studies used a parental report of disease
symptoms. Again, a loss of power can be expected, but case
misclassiﬁcations requiring false reports of both eczema and
asthma in the same individual are unlikely.
Since we used a strict atopic march deﬁnition of early-onset
eczema and childhood asthma, a relatively small number of cases
fulﬁlled our case deﬁnition. Using a wider deﬁnition of the atopic
march (deﬁned as eczema and asthma at any age up to 16 years)
nearly doubled the number of cases in the discovery set and
in the ﬁrst replication to 2,075 and 1,591 cases, respectively
(Supplementary Table 1). Applying the same quality control
criteria and selection thresholds as in the strict deﬁnition,
identiﬁed only ﬁve of the seven loci without evidence of
additional susceptibility regions (Supplementary Table 11). Thus,
our study demonstrates that the strict deﬁnition of a severe
phenotype is a successful approach for studying complex diseases.
In summary, our study revealed two novel loci, which are
speciﬁc for the atopic march phenotype. In addition, we found
loci that were also associated with eczema alone or asthma alone,
which may reﬂect heterogeneity of disease mechanisms under-
lying the atopic march. A strong contribution of eczema genes to
the atopic march suggests that the development of eczema may
play an important role in this unfavourable disease course.
Methods
Phenotype deﬁnition. The term ‘atopic march’ refers to the sequential
manifestations of different allergic diseases such as eczema, asthma and rhinitis58.
Typically, eczema is the ﬁrst allergic disease in infancy, followed by asthma and/or
rhinitis in childhood10,48,59,60. More than 20% of the children with eczema develop
asthma, making this the largest group among children with multiple allergic
conditions10. Since complete longitudinal data were available only for a few study
populations, we aimed to approximate the temporal component of the atopic
march by using eczema up to the age of 3 years and asthma up to the age of
16 years (strict deﬁnition). For a total of 12 study populations, six of the discovery
set and six of the replication set, the corresponding phenotype data were available
(Supplementary Table 1). Another four study populations had no data on early
eczema available. They were included in a separate analysis using a wider deﬁnition
of the atopic march (childhood eczema plus asthma up to the age of 16 years).
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Figure 2 | Ranking of previous eczema and asthma GWAS hits in the
atopic march discovery set. Susceptibility loci identiﬁed in previous GWAS
on eczema or on asthma at genome-wide signiﬁcance (Po5 10 8) are
shown with their P values in the discovery phase (circles). The red line
indicates the threshold for nominally signiﬁcant replication (Po0.05).
Susceptibility loci previously associated with both traits were excluded as
were loci identiﬁed only in populations of non-European descent. Two-sided
P value of the Mann-Whitney U-test (http://vassarstats.net/utest.html) is
reported.
Table 2 | Association of the atopic march loci with eczema alone and asthma alone in the ALSPAC cohort.
SNP ID Chr Locus Original
discovery*
EA AA Atopic march Eczema, no asthma Asthma, no eczema
OR 95% CI P value OR 95% CI P value OR 95% CI P value
rs9357733 6 EFHC1 Atopic march a g 1.27 1.07–1.52 0.0072 0.98 0.83–1.17 0.84 0.97 0.82–1.14 0.71
rs993226 12 SLC6A15/TMTC2 Atopic march g t 1.43 1.06–1.94 0.020 0.82 0.55–1.21 0.31 0.77 0.53–1.13 0.18
FLG combinedw 1 FLG Eczema mut wt 2.89 2.12–3.92 1.2 10 11 1.99 1.42–2.80 7.8 10 5 0.79 0.51–1.23 0.29
rs17690965 5 IL4/KIF3A Eczema c g 1.18 1.02–1.37 0.025 1.12 0.96–1.31 0.15 1.03 0.89–1.19 0.72
rs479844 11 OVOL1 Eczema g a 1.24 1.08–1.42 0.0019 1.24 1.07–1.43 0.0032 1.00 0.87–1.14 0.95
rs2155219 11 C11orf30/LRRC32 Eczema t g 1.23 1.08–1.39 0.0016 1.12 0.98–1.28 0.097 1.05 0.92–1.19 0.49
rs10445308 17 IKZF3 Asthma c t 1.13 0.99–1.29 0.066 0.93 0.81–1.06 0.27 1.30 1.14–1.48 6.5 10 5
AA, alternative allele; EA, effect allele; CI, conﬁdence interval; OR, odds ratio.
*Allergic phenotype ﬁrst associated with SNP.
wORs for FLG combined were estimated based on the two most frequent disease-causing mutations FLG R501X and FLG 2282del4; mut, mutated allele; wt, wild-type allele.
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Controls were selected for the absence of eczema and asthma if phenotype data
were available. Four data sets included unselected, population-based controls.
The phenotype characteristics of each study population are summarized in
Supplementary Table 2. All but one study population of the discovery set had
participated in the previous GWAS on asthma performed by the GABRIEL
consortium61. All study populations were of European ancestry. Informed consent
was obtained from all participants or their legal guardians, and all studies were
approved by the local ethics committees as indicated in the Supplementary
Methods.
Genotyping and imputation. Genotyping and imputation of the study popula-
tions was performed in the context of the GABRIEL consortium or according to the
methods described there61, if not otherwise stated. Brieﬂy, after genotyping, an
ancestry analysis was carried out using EIGENSTRAT2.0 (ref. 62) and putative
non-European samples were eliminated from subsequent analyses. Genotyped
SNPs for imputation had to fulﬁl the following quality control criteria: (1) genotype
missing rate o3% in both cases and controls; (2) minor allele frequency Z1% in
controls; and (3) consistency with Hardy-Weinberg equilibrium by a one degree-
of-freedom goodness-of-ﬁt test in unselected controls (for case–control study
populations) or in the whole population before case–control selection (for study
populations derived from population-based cohorts), respectively (P41 10 4).
Imputation was carried out with MACH63 or IMPUTE64 using Hapmap 2 CEU
SNPs (release 22, NCBI build 36) as reference.
Association analyses. In each study population, association between SNPs and
disease was analysed by logistic regression using an additive model for genotype
dosage. Imputed SNPs with a quality score of r2o0.8 were ﬁltered out. For data
sets comprising unrelated and related cases and controls, we used a logistic
regression model with robust sandwich estimation of the variance65 as
implemented in the Stata logit function to model clustering of family genotypes.
A detailed description of the study populations, including phenotype characteristics
and genotyping platforms, and software used for imputation and logistic regression
analysis is provided in the Supplementary File.
Meta-analyses. Meta-analyses were carried out with METAL66 using the inverse
variance ﬁxed effects model. Combined ORs and 95% CIs were calculated. All SNPs
with missing data in any of the study populations of the discovery set were
excluded. For SNPs with a minor allele frequency of o5%, a quality score of
r2Z0.9 was required in all data sets, for all other SNPs one data set with r2o0.9
was allowed. In addition, we tested for heterogeneity between cohorts using
Cochran’s Q statistic and excluded loci with evidence for effect heterogeneity
(Po0.05). The genomic inﬂation factor was calculated for each cohort and for the
combined analysis. We applied a threshold of Po5 10 8 to declare an effect as
genome-wide signiﬁcant. SNPs with Po1 10 4 in the discovery set meta-
analysis were selected for replication. When multiple associated SNPs were located
in the same region, we selected the best SNP per 1-Mb window. In total, 54 SNPs
were selected and analysed using data from ﬁve additional GWAS sets. Two of
these SNPs, which were signiﬁcant after correcting for the number of SNPs in the
replication set (Po0.05/54¼ Po9.3 10 4; Bonferroni correction), were
genotyped in one more study population (Supplementary Fig. 1). Association
analyses were again performed for each replication study separately using a logistic
regression model. A meta-analysis was conducted for the replication set and for all
studies combined as described above. We applied a genome-wide signiﬁcance
threshold of Po5 10 8 in the combined meta-analysis and tested for overall
heterogeneity of the discovery and replication studies using the Cochran’s Q
statistic. Within the EDC in chromosomal region 1q21.3, we performed an
association analysis adjusted for the effects of the most common mutations in the
ﬁlaggrin gene (FLG), 2282del4 and R501X. FLG genotypes were available in
ALSPAC, BAMSE, PIAMA and in a subset of the German samples with genome-
wide data. The combined FLG mutation status was included as a covariate in the
logistic regression analysis using an additive model.
Genotyping of the FLG mutations R501X and 2282del4. The two most frequent
FLG-null mutations in Europeans, R501X and 2282del4, were genotyped in
ALSPAC67, the Children/Barn, Allergy, Milieu, Stockholm, an Epidemiological
survey Study (BAMSE)68, the Prevention and Incidence of Asthma and Mite
Allergy Study (PIAMA)69 and in the German set comprising the cases of the
German GWAS and controls of the Population Genetics (POPGEN)/Cooperative
health research in the region of Augsburg (KORA) studies14 as originally
described8,70.
Subphenotype analysis in the ALSPAC birth cohort. We analysed the
association of the atopic march, eczema alone and asthma alone in the population-
based birth cohort ALSPAC. For atopic march cases (n¼ 563) and for controls
(n¼ 2,293), we used the same deﬁnition as in the present GWAS. For the eczema
alone analysis, cases had to fulﬁl the early eczema deﬁnition and have a negative
report on asthma (n¼ 494). For the asthma alone analysis, cases had to fulﬁl the
childhood asthma deﬁnition and have a negative report on eczema (n¼ 587).
In addition, we performed case-only analyses for the atopic march cases versus
eczema alone and versus asthma alone. Effect sizes and CIs were assessed by
logistic regression using PLINK.
Applying the same phenotype deﬁnitions, we assessed the effect of infantile
eczema on childhood asthma by using a chi-square test.
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